Michael Böhm - About the Symplicity HTN-3 press release

Michael Böhm (Germany) answers the following questions:

- How does the Symplicity HTN-3 update affect your work? Do you continue renal denervation?

- Further indications for renal denervation?

- Can you please summarise the main points of the ReAdapt CHF trial?